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Abstract
BCR-ABL1-like B-cell precursor acute lymphoblastic leukemia (BCP-ALL) remains poorly characterized in adults. We
sought to establish the frequency and outcome of adolescent and adult BCR-ABL1-like ALL using a novel RNA-Seq
signature in a series of patients with BCP-ALL. To this end, we developed and tested an RNA-Seq custom panel of 42
genes related to a BCR-ABL1-like signature in a cohort of 100 patients with BCP-ALL and treated with risk-adapted ALL
trials. Mutations related to BCR-ABL1-like ALL were studied in a panel of 33 genes by next-generation sequencing
(NGS). Also, CRLF2 overexpression and IKZF1/CDKN2A/B deletions were analyzed. Twenty out of 79 patients (12–84
years) were classified as BCR-ABL1-like (25%) based on heatmap clustering, with significant overexpression of ENAM, IGJ,
and CRLF2 (P ≤ 0.001). The BCR-ABL1-like subgroup accounted for 29% of 15–60-year-old patients, with the following
molecular characteristics: CRLF2 overexpression (75% of cases), IKZF1 deletions (64%), CDKN2A/B deletions (57%), and
JAK2mutations (57%). Among patients with postinduction negative minimal residual disease, those with the BCR-ABL1-
like ALL signature had a higher rate of relapse and lower complete response duration than non-BCR-ABL1-like patients
(P= 0.007). Thus, we have identified a new molecular signature of BCR-ABL1-like ALL that correlates with adverse
prognosis in adult patients with ALL.
Introduction
The 2016 World Health Organization (WHO)classifi-
cation of acute leukemias recognizes nine different enti-
ties within B-cell precursor acute lymphoblastic leukemia/
lymphoma (BCP-ALL) and two new provisional entities,
including BCR-ABL1-like. These 11 subtypes are based on
specific molecular alterations, mainly chromosome rear-
rangements, that promote the formation of aberrant chi-
meric proteins and aneuploidies1. Next-generation
sequencing (NGS) and array technologies have been
instrumental in identifying new ALL subtypes, and have
aided in the discovery of new leukemogenic mechanisms.
It has been known for many years that a subset of patients
with ALL (~25% of BCP-ALL) have no established
abnormalities, commonly referred to as B-other ALL. The
genomic landscape of B-other ALL is becoming increas-
ingly clear, and the proportion of unclassifiable patients
has declined significantly2,3. In this context, BCR-ABL1-
like B-ALL has emerged as one of the most relevant new
subtypes due to its frequency and the potential benefit of
targeted therapies (i.e., ABL and JAK inhibitors).
Philadelphia chromosome-positive ALL is defined by
the t(9;22)(q34;q11) translocation that encodes BCR-
ABL1 oncogene, a constitutively active kinase. This
aberration is present in >95% of patients with chronic
myeloid leukemia, and in 3–5% and 25% of pediatric and
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adult ALL cases, respectively. In 2009, the DCOG/Eras-
mus and COG/St. Jude groups independently discovered a
high risk BCR-ABL1-negative subgroup in children with
B-ALL, exhibiting a gene expression signature similar to
that of BCR-ABL1 positive-ALL but lacking the BCR-
ABL1 rearrangement4. This subtype is associated with
downregulation of B-cell development genes and over-
expression of stem- and progenitor-cell genes. Clinically,
this ALL subtype presents with high-risk clinical features
such as high white blood cell (WBC) count, poor response
to induction chemotherapy, higher measurable residual
disease levels, and low probability of survival4–8.
The frequency of BCR-ABL1-like ALL has been repor-
ted as 20–30% in adults, with a peak of incidence in the
adolescent and young adult population (up to 42%)9–12.
The BCR-ABL1-like ALL subtype shows deletions in
several transcription factors involved in B-cell develop-
ment, including IKZF1, E2A, EBF1, and PAX513. Addi-
tionally, the main molecular characteristics of BCR-ABL1-
like ALL are the multiple translocations in different
cytokine receptor and kinase signaling genes such as
ABL1 (excluding BCR association), JAK2, ABL2, PDGFRB,
TYK2, CSF1R, CRLF2, and EPOR. These mutations trigger
the activation of growth promoting kinase or cytokine
signaling pathways14. CRLF2 translocation and mutations
in the JAK family genes are recurrent and result in the
activation of JAK-STAT pathways in patients with BCR-
ABL1-like B-ALL15–17.
Several different approaches have been employed for
the characterization of BCR-ABL1-like ALL. Patients
were classified using hierarchical clustering on a gene
expression array in early studies6,8. A simpler approach
was subsequently optimized based on Low Density
Arrays carrying a small number of genes selected by
microarray prediction analysis15,18. In the present study,
we designed a targeted NGS RNA-Seq panel of 42 genes
to classify patients with BCR-ABL1-like ALL. We sought
to identify the BCR-ABL1-like ALL signature by targeted
expression in a series of adolescent and adult patients
with BCP-ALL, but without recurrent genetic abnorm-
alities defined by the WHO classification (henceforth B-
other ALL), and to evaluate its clinical, prognostic and
therapeutic relevance.
Patients and methods
Patients and study design
We examined bone marrow (BM) or peripheral blood
(PB) samples from adolescent and adult patients newly
diagnosed with B-other ALL and treated between 2003
and 2017 in several Spanish hospitals. Patients received
frontline chemotherapy according to PETHEMA (Pro-
grama Español de Tratamientos en Hematología) ALL
risk and minimal residual disease (MRD)-oriented
trials19,20. A first series of patients treated between 2002
and 2012 was evaluated for the identification of the BCR-
ABL1-like signature (n= 49), and a second series of
patients treated between 2012 and 2017 was used for
validation (n= 100).
The study design is shown in Fig. 1. One hundred
patients with BCR-ABL1-negative B-ALL were selected
for molecular studies. Of those, 16 were discarded [Bur-
kitt Lymphoma (n= 4), undifferentiated acute leukemia
(n= 2), ALL with MLL rearrangements (n= 2), TCF3-
PBX1 (n= 1), ETV6/RUNX1 (n= 1), hyperdiploidy (n=
3) and hypodiploidy (n= 1) not classified as BCR-ABL1-
like based on the RNA-Seq signature, and two patients
with low quality clinical data]. The remaining 84 patients,
classified as B-other ALL, were considered valid for BCR-
ABL1-like signature identification by RNA-Seq. Of these,
28 were discarded for survival analysis due to the het-
erogeneity of treatment protocols (including palliative
therapy) and the absence of MRD assessment. Therefore,
the prognostic relevance of the BCR-ABL1-like signature
was investigated in a cohort of 56 homogeneously treated
patients (median age 34 years; range 16–59 years). The
main clinical characteristics and prognosis of patients
with BCR-ABL1-like B-ALL are shown in Table 1.
Details for patient samples are provided in Supple-
mentary Table S1. The study was conducted in accor-
dance with the principles of the Declaration of Helsinki,
and the protocols were approved by the appropriate
institutional review boards. All patients provided written
informed consent for the analysis of their biological
specimens.
MRD assessment by multiparametric flow cytometry
BM MRD levels were centrally assessed at the end of
induction (weeks 5–6) in complete remission (CR)
patients and at the end of the third consolidation cycle
(weeks 16–18) by multiparameter flow cytometry. MRD
levels at this latter time point were used to assign post-
consolidation therapy (continuation chemotherapy or
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Fig. 1 Study flow chart. Design and distribution of the patients. BCP-
ALL: B-cell precursor acute lymphoblastic leukemia; NGS: Next-
generation sequencing; Ph: BCR-ABL1.
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Median [range] 34 [16; 59] 22 [17; 59] 38.5 [16; 58] 0.310
Age range (years)
15–35 30 (54%) 11 (69%) 19 (47%) 0.150
36–59 26 (46%) 5 (31%) 21 (53%)
Sex
Male 27 (48%) 10 (63%) 17 (42%) 0.176
Female 29 (52%) 6 (37%) 23 (58%)
WBC·10−3/µL (n= 52)
Median (range) 7.87 [0.60-393.30] 13.40 [1.90-388] 5.01 [0.60-393.30] 0.071
CRLF2/GAPDH
Negative (≤0,1%) 35 (63%) 4 (25%) 31 (78%) <0.001
Positive (>0,1%) 21 (37%) 12 (75%) 9 (22%)
PB Blasts (%) (n= 56)
Median [range] 41 [0; 95] 72 [24; 95] 34 [0; 90] 0.002
BM Blasts (%)(n= 30)
Median [range] 93 [60; 100] 96,5 [93; 98] 92 [60; 100] 0.069
Phenotype
Common 37 (66%) 10 (63%) 27 (68%) 0.417
Pre-B 12 (21%) 5 (31%) 7 (17%)
Pro-B 7 (13%) 1 (6%) 6 (15%)
Karyotype (n= 49; n= 15 BCR-ABL1-like; n= 34 remaining B-ALL)
Normal 12 (25%) 3 (20%) 9 (27%) 0.428
IGHr 4 (8%) 1 (7%) 3 (9%)
Complexa 2 (4%) 0 (0%) 2 (6%)
No Growth 14 (29%) 3 (20%) 11 (32%)
Otherb 17 (35%) 8 (53%) 9 (27%)
Risk classification
High 46 (82%) 13 (81%) 33 (83%) 1.000
Intermediate 10 (18%) 3 (19%) 7 (17%)
MRDc postinduction (n= 41; BCR-ABL1-like n= 11; Remaining B-ALL n= 30)
Positive 18 (44%) 8 (73%) 10 (33%) 0.036
Negative 23 (56%) 3 (27%) 20 (67%)
MRDc post-consolidation (n= 36; BCR-ABL1-like n= 8; Remaining B-ALL n= 28)
Positive 10 (28%) 2 (25%) 8 (29%) 1.000
Negative 28 (72%) 6 (75%) 20 (71%)
IKZF1 gene deletiond
Positive 23 (52%) 9 (64%) 14 (47%) 0.276
Negative 21 (48%) 5 (36%) 16 (53%)
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detection limit of the method was 1 × 10−4. MRD level
was considered positive when exceeded 0.01% or 1 × 10−4
at the end of induction and after consolidation.
Molecular biology analyses
CRLF2 overexpression
One microgram of RNA was retrotranscribed to eval-
uate the expression levels of CRLF2 relative to GAPDH, by
real-time quantitative PCR (qPCR). The probes were
acquired from Gene Expression Taqman Assays (Thermo
Fisher, Palo Alto, CA): Hs00845692_m1 (CRLF2), and
Hs02786624_g1 (GAPDH). Overexpression was deter-
mined by means of 2−ΔΔCt method21, and was defined as
positive when it was ≥0.1% relative to GAPDH gene
expression.
Multiplex ligation-dependent probe amplification (MLPA)
One hundred ng of DNA was used for MLPA according
to manufacturer instructions (MRC Holland, Amsterdam,
the Netherlands). Two different kits have been used, one
of them SALSA MLPA P335-C1 ALL-IKZF1 probemix kit
contains 57 MLPA probes with amplification products
between 120 and 504 nucleotides of the main exons of
EBF1, JAK2, CDKN2A, CDKN2B, PAX5, ETV6, BTG1,
RB1, IKZF1/2/3 genes, and genes of the X/Y PAR1 region
(CRLF2, CSF2RA, IL3RA and P2RY8). The second Kit
SALSA MLPA P202 probemix kit contains 59 MLPA
probes with amplification products between 118 and 504
nucleotides, which span IKZF1 and CDKN2A-B genes (21
and 3 probes, respectively).
Targeted RNA-sequencing
cDNA was obtained after reverse transcription of 1 µg of
RNA. cDNA integrity was checked by qPCR with a GUSB
Taqman probe (Hs00939627_m1) (Thermo Fisher Scien-
tific), discarding cDNA with a Ct>25 at a threshold of 0.1.
A barcoded cDNA library was then generated by amplifi-
cation using Ion AmpliSeq® (Thermo Fisher Scientific)
technology to precisely maintain expression levels of the
targeted genes. A targeted RNA-Seq customized panel was
designed with 38 genes plus 4 housekeeping genes, gen-
erating 42 primer pair amplicons. The tested genes were as
follows (in alphabetical order): ABCA9, ARHGEF12,
BMPR1B, CA6, CD99, CHN2, CRLF2, DCTN4, DENND3,
ECM1, ENAM, GAB1, GBP5, GPR110, IFITM1, IGJ, IL7R,
LDB3, MDFIC, MMP28, MUC4, NRXN3, PON2, RBM47,
RNF157, S100Z, SEMA6A, SCHIP1, SH2B3, SLC2A5,
SLC37A3, SOC2, SPATS2L, TAF5L, TMEM154, TP53INP1,
TTYH2, and WNT9A22. The control genes were GUSB,
JUN, PBGD, and TBP. Two of the 42 genes (SCHIP1 and
IFITM1) were discarded from analysis due to the low
number of reads in each of the runs.
The quality of the amplified cDNA libraries was eval-
uated using Bioanalyzer High Sensitivity chips (Agilent
Technologies, Santa Clara, CA) and quantified with Ion
Library TaqMan™ Quantitation Kits (Thermo Fisher Sci-
entific). Libraries were diluted to 100 pM and pooled
equally, assigning 150,000 reads per sample. Pooled
libraries were amplified using the Ion Chef System with
the Ion 540 Sequencing Kit (Thermo Fisher Scientific).
Enriched libraries on a chip were sequenced on the Ion
GeneStudio S5 System using the Ion S5 Sequencing Kit
(Thermo Fisher Scientific) with 500 flows. The absolute
normalized Reads Per Million (RPM) matrix was obtained
from RNA-Seq Analysis plug-in (v5.4.0.1) within Torrent
Suite software (v5.10) (Thermo Fisher Scientific). The
matrix was subsequently normalized intra-patient relative
to GUSB because it was the housekeeping gene with the
higher Spearman correlation coefficient (ρ) of the reads
between patients within the matrix data, compared to the
other three genes. A final analysis was performed using the










Positive 19 (43%) 8 (57%) 11 (37%) 0.202
Negative 25 (57%) 6 (43%) 19 (63%)
IKZF1 and CDKN2A/B codeletiond
Positive 11 (25%) 5 (36%) 6 (20%) 0.287
Negative 33 (75%) 9 (64%) 24 (80%)
BM bone marrow, IGHr rearrangements of IGH@ gene, MRD minimal residual disease, PB peripheral blood, WBC white blood cells.
aComplex karyotype is defined as more than four chromosomic alterations.
bOther: del 12p (n= 1); del6q (n= 1); del7p plus del9p (n= 1); del9p (n= 2); del6q plus del 12p (n= 1); other deletions (n= 3); other rearrangements (n= 4); other
alterations (n= 4).
cPositive MRD ≥ 0.01 by multiparametric flow cytometry.
dIKZF1 and CDKN2A/B deletions n= 44; BCR-ABL1-like n= 14; remaining B-ALL n= 30.
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org/morpheus/), a matrix visualization and analysis plat-
form, obtaining an unsupervised hierarchical cluster
heatmap using one minus Pearson correlation as a metric,
and an average of the data as the linkage method. The raw
RNA-Seq sequencing data were uploaded to NCBI with
BioProject ID: PRJNA613841.
Targeted DNA-sequencing
A total of 33 lymphoid-related genes were sequenced by
targeted NGS using an Ion Ampliseq® On Demand panel
(Thermo Fisher Scientific), consisting of a custom mixture
of oligonucleotides that generated 892 amplicons in two
pools, covering 182 kb. The design includes whole exons
of JAK1, NRAS, XPO1, CXCR4, SF3B1, MYD88, KLHL6,
WHSC1, FBXW7, IRF4, IKZF1, CRLF2, BRAF, EZH2,
JAK2, CDKN2A, PAX5, NOTCH1, ATM, KRAS, KMT2D,
CREBBP, TP53, STAT5B, STAT3, TYK2, and JAK3 genes,
and selected exons of RAB39A, CUL5, EXPH5, DLEU1,
SAT2, and EFNB3.
Libraries were prepared following the Ampliseq® pro-
tocol using at least 10 ng of template DNA per reaction.
Multiple indexed libraries were pooled and sequenced on
the Ion GeneStudio S5 System using Ion S5 Sequencing
Kit, with 500 flows. Samples were sequenced to an average
1900× coverage. Alignment and variant detection were
performed using Ion Reporter v5.10 using the human
reference genome (hg19). Variants were manually
reviewed in Integrated Genome Viewer v2.3.81 (Broad
Institute, Cambridge, MA). Variants were classified as
benign, unknown significance, pathogenic or likely
pathogenic according to VARSOME software23. The raw
DNA-Seq sequencing data were uploaded to NCBI with
BioProject ID: PRJNA614523.
Statistical analyses
Baseline characteristics were reported as frequency and
percentage for categorical variables and as median and
range for quantitative variables. Comparisons of propor-
tions and the medians of variables between different
groups were performed using the χ2 test, Fisher’s exact
test, or the nonparametric median test as appropriate.
Overall survival (OS) was measured from the time of
diagnosis to the time of death from any cause. Disease-
free survival (DFS) was measured from the date of
achievement of the first remission until the date of relapse
or death from any cause. Cumulative incidence of relapse
(CIR) was calculated from the date of achievement of the
first remission until the date of relapse. Patients who died
without relapse were counted as a competing risk.
Patients not known to have relapsed ordied at last follow-
up were censored on the date they were last examined. OS
and DFS curves were performed using the Kaplan–Meier
estimation, and the log-rank test was used for compar-
isons between groups. CIR curves were estimated using
cumulative incidence rates and were compared by Gray’s
test. Two-sided P-values < 0.05 were considered statisti-
cally significant. Multivariable analyses were performed
using the Cox proportional hazards model for OS and
DFS, and the Fine and Gray model for CIR. The statistical
package SPSS version 24.0 (Statistical Package for Social
Sciences Inc., Chicago, IL) and R 3.4.2 software were used
for all analyses.
Results
BCR-ABL1-like signature identification by RNA-Seq
To identify a specific molecular signature for BCR-
ABL1-like B-ALL, we examined a dataset from patients
with B-other ALL (n= 49) by targeted RNA-Seq that,
after clustering, grouped a subset of patients with over-
expression of CRLF2 and mutations in several genes
related to the BCR-ABL1-like signature. Thirteen of these
patients (27%) were classified as BCR-ABL1-like based on
heatmap clustering, with all equally showing over-
expression of ENAM and IGJ. Also, most of the patients
with high CRLF2 expression (CRLF2+) were classified
into the BCR-ABL1-like ALL subgroup: 11/13 (85%) ver-
sus 7/36 (19%) non-BCR-ABL1-like, P < 0.001. Mutations
of IKZF1, KRAS, JAK2, CRLF2, NRAS, JAK1, TYK2, and
PAX5 genes related to BCR-ABL1-like genotype were
present in 7/11 BCR-ABL1-like patients (64%) versus 3/20
non-BCR-ABL1-like patients (15%), P= 0.013. This sig-
nature identified BCR-ABL1-like patients who showed
significantly shorter DFS probability at 5 years [95%con-
fidence interval (CI): 20% (0%; 45%) vs 54% (95% CI: 35%;
73%), P= 0.047].
BCR-ABL1-like signature by RNA-Seq, validation cohort
We next validated the reproducibility of the identified
signature by extending the study cohort to 100 BCR-
ABL1-negative patients (Fig. 1). Targeted RNA-
sequencing was performed on cDNA from 84 patients.
Those patients with WHO cytogenetic subtypes (i.e., MLL
rearrangements, ploidies, Burkitt ALL), with other
hemopathies, or with BCP-ALL with incomplete follow-
up data were excluded. A normalized matrix (input for
heatmap clustering) was obtained for 79/84 of these
patients after removing data for five patients due to the
low quality of the generated reads. One of the groups
generated in the heatmap was classified as BCR-ABL1-like
and accounted for 20/79 patients (25%) (Fig. 2). The
expression of ECM1, ENAM, IGJ, and CRLF2 was sig-
nificantly higher in the BCR-ABL1-like subgroup than in
the non-BCR-ABL1-like subgroup (P ≤ 0.015). By contrast,
MDFIC was underexpressed in 100% of patients with the
BCR-ABL1-like signature (P= 0.001). In addition, this
group was enriched inpatients who were CRLF2+ [15/20
(75%) vs 16/59 (27%), P < 0.001]; and in mutations related
to the BCR-ABL1-like signature16 such as JAK2 and RAS,
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or PAX5 and IKZF1 genes [14/18 (78%) vs 16/42 (38%),
P= 0.005]; and both alterations [13/18(72%) vs 6/42
(14%), P < 0.001]. Most of the BCR-ABL1-like patients
agree on the result of CRLF2 overexpression (17/20: 85%)
by both techniques qPCR and RNA-Seq.
Clinical characteristics and prognosis of patients with
BCR-ABL1-like ALL
Outcome analysis was performed in patients between 15
and 60 years of age treated in PETHEMA trials with
intermediate (10/56, 18%) and high-risk (46/56, 82%)
protocols, in order to ensure homogeneity between
treatments. With a median follow up of 3.8 years [range,
0.82–14.94], the 4- and 8-year OS of the 56 patients with
BCP ALL were 58% (95% CI: 44%; 72%) and 37% (95% CI:
17%; 57%), respectively; the 4- and 8-year DFS were 47%
(95% CI: 32%; 62%) and 39% (95% CI: 20%; 58%),
respectively; and the CIR was 45% (95% CI: 30%; 59%) for
both time points. A summary of the clinical data is shown
in Table 1.
Sixteen of the 56 patients (29%) were classified as BCR-
ABL1-like in the heatmap (Supplementary Fig. 1).
There were no significant differences in baseline char-
acteristics such as age, gender, ALL phenotype, % BM
blasts, cytogenetics, and risk classification in BCR-ABL1-
like patients in comparison with the remaining patients in
the B-other ALL subgroup. However, significant differ-
ences were observed in the median percentage of blasts in
PB between BCR-ABL1-like and non-BCR-ABL1-like
groups (72% vs 34%, P= 0.002), and WBC counts
[13.40 × 109/L (95% CI: 1.9; 388.0) vs 5.01 × 109/L (95%
CI: 0.6; 393.3), P= 0.071].
Although there were no significant differences in CR
achievement, BCR-ABL1-like patients had a tendency for
a poorer response to induction treatment than non-BCR-
ABL1-like patients [3/16 (19%) non-responders in BCR-
ABL1-like vs 2/40 (5%) in non-BCR-ABL1-like patients,
P= 0.135]. In addition, BCR-ABL1-like patients showed a
higher proportion of positive MRD than non-BCR-ABL1-
like patients [8/11 (73%) vs 10/30 (33%), P= 0.036] at the
end of induction phase. Interestingly, among patients with
postinduction negative MRD (MRD-) (n= 26), BCR-
ABL1-like patients (n= 6) had a higher rate of relapse
and lower CR duration than non-BCR-ABL1-like patients
(n= 20) (P= 0.007) (Fig. 3). Nine out of 51 CR patient-
sunderwent allogeneic-HSCT with no significant differ-
ences in the proportion of transplanted patients between
BCR-ABL1-like and the remaining B-other ALL patients
[2/13(15%) vs 7/38 (18%), respectively, P= 1.000].
BCR-ABL1-like patients showed poorer OS than the
remaining BCP-ALL patients [47% (95% CI: 21%; 73%) vs
63% (95% CI: 48%; 78%), P= 0.105], with a higher fre-
quency of relapses [66% (95% CI: 29%; 87%) for BCR-
ABL1-like vs 38%(95% CI: 21%; 55%) for B-other ALL,
P= 0.067] and the consequent lower DFS [26% (95% CI:
1%; 51%) vs 54% (95% CI: 36%; 72%), P= 0.069] as the
main reasonsfor the poorer OS (Fig. 4). The limited
number of patients in this series and the relatively low
BCR-ABL1-like
signature
Color Key – Expression levels
Fig. 2 Unsupervised hierarchical cluster with dendrogram of 79 B-other-ALL patients based on gene expression of 40 genes. The 20 BCR-
ABL1-like patients are marked with a blue square.
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ratio of mutations did not allow us to assess the possible
prognostic significance of JAK/STAT pathway mutations,
N/KRAS, IKZF1, or PAX5 point mutations. The univari-
able and multivariable models for the 56 patients are
shown in Supplementary Tables S2 and S3.
CRLF2 overexpression: association with BCR-ABL1-like,
JAK/STAT mutation pathway and prognosis
Among the 56 B-other ALL patients with clinical data,
most of the BCR-ABL1-like patients showed CRLF2
overexpression clustered in the BCR-ABL1-like subgroup
[12/16(75%) vs 9/40(22%) non-BCR-ABL1-like patients,
P < 0.001]. There were available samples for NGS mole-
cular studies of DNA for 42/56 patients (14/16 BCR-
ABL1-like and 24/40 non-BCR-ABL1-like). A total of 57
non-synonymous variants affecting 15 genes were iden-
tified among the 42 patients. At least one variant could be
identified in 79% (33/42) of the patients, and at least one
pathogenic mutation was identified in 57% (24/42). The
distribution of the mutated genes is shown in Fig. 5a and
in more detail in Supplementary Table S4. JAK2 muta-
tions (more recurrently c.2047A > G and p.R683G) were
enriched in BCR-ABL1-like ALL patients [9/14(64%) vs
non-BCR-ABL1-like 3/28(11%), P= 0.001]. The distribu-
tion of JAK2 mutations across the protein domains is
shown in Fig. 5b.
Significant differences in overexpression of CRLF2 were
found between BCR-ABL1-like and non-BCR-ABL1-like
groups (see Supplementary Table S5, P < 0.001), and
additional mutations were found in JAK-STAT, RAS, and
transcription factors such as IKZF1 or PAX5. Statistically
significant differences were found in the rate of JAK/
STAT mutations between BCR-ABL1-like patients and
the remaining B-other ALL patients [BCR-ABL1-like 9/14
(64%) vs 3/28 (11%), P= 0.001], but not for RAS genes or
lymphoid transcription factors.
We found significant differences in DFS for CRLF2
overexpression [4-year DFS 28% (95% CI: 6%; 50%) vs 59%
(95% CI: 40%; 78%) and 8-year DFS 28% (95% CI: 6%;
50%) vs 47% (95% CI: 22%; 72%), P= 0.006] (Supple-
mentary Fig. 2b). CRLF2+ patients had higher 4- and
8-year CIR than patients with no CRLF2 overexpression
[61% (95% CI: 33%; 81%) vs 35% (95% CI: 17%; 54%),
Fig. 3 Cumulative incidence of relapse for BCR-ABL1-like and
non-BCR-ABL1-like patients within the post-induction negative-
MRD population. BCR-ABL1-like patients are denoted by the green
line and non-BCR-ABL1-like patients by the blue line.
Fig. 4 Kaplan–Meier survival curves for BCP-ALL patients: BCR-ABL1-like patients are denoted by the green line and non-BCR-ABL1-like
patients by the blue line. a Overall survival; b disease-free survival.
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P= 0.018; at both time points] (Supplementary Fig. 2c).
Although CRLF2+ patients showed lower OS than those
without overexpression, the differences were not statisti-
cally significant [4-year OS 52% (95% CI: 29%; 75%) vs
62% (95% CI: 46%; 78%) and 8-year OS 20% (95% CI: 0%;
51%) vs 45% (95% CI: 20%; 70%), P= 0.234].
Of note, no differences were observed in CR achieve-
ment, MRD clearance or outcome between CRLF2+/BCR-
ABL1-like and CRLF2+/non-BCR-ABL1-like patients
(data not shown).
Prognostic impact of other molecular alterations: IKZF1 and
CDKN2A/B deletions
Analysis of copy number alterations by MLPA was
available for 44/56 B-other ALL patients. Results showed
that 75% of these patients (33/44) had at least one deletion
in IKZF1 or CDKN2A/B, but no significant differences
were found between BCR-ABL1-like and non-BCR-ABL1-
like groups, or for individual deletions in the case of
codeletion of both genes (Table 1).
As shown in univariable and multivariable analysis
(Supplementary Tables S2 and S3), CDKN2A/B deletions
showed statistical significance for outcome prediction in
the 56 B-other ALL patients. However, we observed sig-
nificant differences regarding the impact of these dele-
tions within BCR-ABL1-like and non-BCR-ABL1-like
subgroups individually. Although the number of patients
was low, BCR-ABL1-like patients with CDKN2A/B
deletion (n= 6) showed lower OS than equivalent
patients without loss of CDKN2A/B (n= 8) [4-year OS
17% (95% CI: 0%; 46%) vs 83% (95% CI: 53%; 100%), P=
0.041]. However, these differences showed a trend for DFS
and were not statistically significant for CIR, in which
patients with CDKN2A/B loss had higher relapse inci-
dence in both subgroups individually. By contrast, the
prognostic differences on OS and DFS observed for BCR-
ABL1-like were not observed within the non-BCR-ABL1-
like patients, although non-BCR-ABL1-like patients with
CDKN2A/B deletion showed a trend towards higher CIR
than those without CDKN2A/B loss (data not shown).
IKZF1 deletions did not have prognostic significance for
any outcome parameter analyzed in the B-other ALL
series. However, the concomitance of IKZF1 and
CDKN2A/B deletions identified a subset of patients with
poor prognosis. Among the 44 patients with known
IKZF1 and CDKN2A/B status, those having both altera-
tions (n= 11) showed poorer OS than those without both
deletions (n= 33) [4-year OS 46% (95% CI: 17%; 72%) vs
67% (95% CI: 50%; 84%), P= 0.090]. The same scenario
was observed for DFS [3-year DFS 40% (95% CI: 10%;
70%) vs 67% (95% CI: 50%; 84%), P= 0.014] and CIR [3-
year CIR 50% (95% CI: 16%; 77%) vs 30% (95% CI: 15%;
47%), P= 0.061].
Subgroup analysis was repeated for patients with both
deletions, to assess whether the concomitant loss of IKZF1
and CDKN2A/B had adifferent prognosis in BCR-ABL1-like
               1FZKI
              5XAP
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Fig. 5 Main alterations identified in this study with a detail of JAK2 mutations. a Molecular, genetic, and clinical alterations in BCR-ABL1-like and
non-BCR-ABL1-like patients. b Schematic representation of JAK2 primary sequence. Point mutations encountered in the studied population are
depicted in green; p.R683G was observed in five patients.
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and non-BCR-ABL1-like cohorts individually. Again,
although the patient numbers were low, we observed that
within the BCR-ABL1-like subset, patients harboring both
deletions experienced significantly lower probability of
survival than those without both alterations (4/5 vs 5/9
deaths, P= 0.029), mainly due to a higher relapse rate (3/4 i
5/8 relapses, P= 0.043) (Fig. 6). Within the remaining B-
other ALL subgroup, patients with deletion of both genes
also experienced more relapses although the results were
not statistically significant (data not shown).
Discussion
We sought to identify an RNA-Seq signature for BCR-
ABL1-like ALL in a series of homogeneously treated
adolescent and adult patients with B-other ALL, and
analyze its prognostic impact. We demonstrate the
capacity of a simplified targeted RNA-Seq signature to
segregate BCR-ABL1-like patients within a BCP-ALL
adult population. This approach enabled us to confirm
that BCR-ABL1-like is a high-risk ALL subtype also in
young, adolescent, and older adults despite treatment with
modern MRD-oriented protocols.
The prognostic impact of the BCR-ABL1-like subtype
has been mainly reported in pediatric and adolescent
populations, and studies in adult BCP-ALL are scarce6,8,16.
The DCOG/Erasmus and St Jude groups used different
gene profiles to define the BCR-ABL1-like subtype and,
consequently, there is a lack of standardization and com-
parability regarding the best strategy to identify these
patients. The frequency (29%) and clinical outcome of
BCR-ABL1-like ALL found in this study is in accord with
that of the MD Anderson and St. Judereports9,11: Roberts
and coworkers11 characterized 194/798 (24%) patients (age
range 21–86 years) as BCR-ABL1-like, and Jain et al.9
identified 49/148 (33%) patients (age range 15–71 years).
Regarding IKZF1 deletions, the MD Anderson group
classified 73% of patients within the BCR-ABL1-like
population as positive, St. Jude reported 81% of IKZF1
losses, and we found 64% of mutated patients. In our
study, we identified 75% of patients CRLF2+ and 57% with
mutated JAK2, similar to the published results. Indeed,
61% and 51% of CRLF2+ and 45% and 27% of mutated
JAK2 have been reported within BCR-ABL1-like patients
in the St. Jude and MD Anderson studies, respectively.
The prognostic impact of the BCR-ABL1-like ALL subtype
in adults homogeneously treated within MRD-oriented trials
remains still unclear. In our series, these patients had higher
WBC and blast counts than non-BCR-ABL1-like patients,
suggesting a greater degree of cell proliferation with a strong
capacity for dissemination—an essential characteristic rela-
ted to a higher degree of clonal heterogeneity and treatment
resistance. Interestingly, a high degree of cell cycle dereg-
ulation (57% CDKN2A/B deletion) and stem cell-like char-
acteristics as a result of IKZF1 losses (64%) might play an
important role in the aggressiveness and resistance seen in
the present and other series of BCR-ABL1-like patients. As
mentioned, 75% of BCR-ABL1-like patients overexpressed
CRLF2 and 64% had mutations in the JAK-STAT pathway
(and all CRLF2+ patients also had JAK2 mutations), sup-
porting the idea that this is an essential pathway in this
aggressive subtype. Most JAK2 mutations identified in the
present study were pathogenic and involved the tyrosine-
kinase domains 1 and 2, close to the nucleotide binding site
for ATP-ADP exchange (residues 855–863), and structurally
distant from the self-regulatory tyrosine 1007 and 1008.
Currently, several clinical trials are evaluating the efficacy of
JAK and mTOR inhibitors (in addition to TKI inhibitors),
alone or in combination with other drugs based on this
genetic rationale24–26.
IKZF1 and CDKN2A/B deletions are known to be asso-
ciated with poor prognosis in pediatric and adult
B-ALL populations27–29, mainly in the BCR-ABL1 B-ALL
Fig. 6 Log-rank comparison curves between IKZF1 and CDKN2A-B-codeletion positive and negative patients within the BCR-ABL1-like
population. IKZF1/CDKN2A-B codeleted patients are denoted by the green line and patients with no codeletion of IKZF1/CDKN2A-B by the blue line.
a Overall survival; b disease-free survival; c cumulative incidence relapse.
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subpopulation. Our results suggest that, despite the low
number of cases analyzed, CDKN2A/B deletions are mar-
kers of poor survival in B-other ALL, and the association
between CDKN2A/B and IKZF1 deletions might also
contribute to the dismal prognosis of BCR-ABL1-like.
Finally, the survival analysis suggests that all CRLF2+
patients show poor response to standard treatment and bad
prognosis whether or not they are BCR-ABL1-like.
Unfortunately, we did not have enough samples to evaluate
the prognostic significance of additional alterations (i.e.,
JAK2 mutations, IKZF1, and CDKN2A/B deletions) in the
cohort of 56 B-other ALL patients or within the subgroups
of patients with and without CRLF2 overexpression.
Due to the limited number of BCR-ABL1-like patients
in our series, the difference in CR achievement between
BCR-ABL1-like and non-BCR-ABL1-like patients did not
reach statistical significance, although there were four
times as many patients not achieving CR in the BCR-
ABL1-like subgroup. Taken together with the low MRD
clearance at the end of induction seen in BCR-ABL1-like
patients (three-quarters of BCR-ABL1-like patients were
MRD-positive at the end of induction compared with one-
third of non-BCR-ABL1-like patients), this indicates
higher treatment resistance. Given the small number of B-
other patients (n= 10) MRD-positive at the end of con-
solidation, we could not evaluate the role of HSCT on
BCR-ABL1-like and non-BCR-ABL1-like patients.
In addition to treatment resistance, the high degree of
relapse observed in BCR-ABL1-like patients and, more
importantly, those who were MRD-negative at the end of
induction, suggests that standard treatments are not less
efficient for this ALL subtype. Also, while MRD has
become the most powerful outcome predictor in ALL, it is
not fully predictive, and other factors beyond MRD (e.g.,
genetic alterations) also impact patients’ prognosis,
especially in the B-other subpopulation.
The BCR-ABL1-like signature methodology clearly dis-
tinguishes the outcome of patients in whom no recurrent
genetic abnormalities could be identified by standard
methods. Specifically, loss of CDKN2A/B identifies
patients at high risk of disease progression among those
with non-available genetic risk categorization. We also
provide more detailed information on the prognostic
impact of IKZF1 and CDKN2A/B deletions (together and
separately), specifically within the BCR-ABL1-like subtype,
where they seem to confer poor outcome. By contrast, the
prognostic relevance of these alterations in the non-BCR-
ABL1-like subgroup is less clear. Due to the paucity of
samples, more studies are needed to address these issues.
Currently, methodical characterization BCR-ABL1-like
is expensive and laborious. The multiple rearrangements
present in this subtype and the constellation of other
molecular alterations characteristic but not exclusive of
this entity make NGS an attractive option, although this
requires complex bioinformatic analysis. Interestingly, the
approach shown here enables the identification of the
BCR-ABL1-like signature by targeted RNA-Seq in 3 days
upon sample arrival with a simple and fast NGS library
protocol and subsequent sequencing. It is also repro-
ducible, as we have shown in the validation cohort.
Finally, a simple computer plug-in will output a normal-
ized matrix that will predict patient outcome in the
hierarchical clustering heatmap.
In summary, our study demonstrates that targeted
RNA-Seq correctly identifies BCR-ABL1-like ALL in BCP-
ALL patients. This methodology is inexpensive, available,
and feasible, and could be introduced in the routine
clinical workout for ALL patients. We have also con-
firmed the poor prognosis of BCR-ABL1-like ALL in the
adult setting. An early diagnosis of BCR-ABL1-like ALL
could be critical to initiate appropriate treatment
depending on the kinase profile (i.e., JAK inhibitor,
tyrosine-kinase inhibitor, etc.). These results endorse the
inclusion of these molecular approaches in further clinical
protocols for adopting early clinical decisions with the
goal to better manage patients with ALL.
Supplementary information is available at Blood Cancer
Journal website.
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